Cresset Asset Management LLC Trims Holdings in DaVita Inc. (NYSE:DVA)

Cresset Asset Management LLC trimmed its position in DaVita Inc. (NYSE:DVA) by 73.5% in the 4th quarter, HoldingsChannel reports. The firm owned 3,517 shares of the company’s stock after selling 9,752 shares during the quarter. Cresset Asset Management LLC’s holdings in DaVita were worth $526,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. United Capital Financial Advisors LLC raised its stake in shares of DaVita by 2.6% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company’s stock worth $361,000 after purchasing an additional 62 shares during the last quarter. Freedom Investment Management Inc. raised its stake in shares of DaVita by 3.6% in the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company’s stock worth $268,000 after purchasing an additional 62 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in shares of DaVita by 8.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock worth $133,000 after purchasing an additional 68 shares during the last quarter. Impact Partnership Wealth LLC raised its stake in shares of DaVita by 3.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock worth $290,000 after purchasing an additional 70 shares during the last quarter. Finally, Contravisory Investment Management Inc. raised its stake in shares of DaVita by 1.2% in the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock worth $910,000 after purchasing an additional 73 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research note on Friday, February 21st. StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Friday, April 25th. Cowen reiterated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, Barclays lifted their price target on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $166.33.

DaVita Stock Down 2.7%

DaVita stock opened at $140.10 on Thursday. The stock has a market capitalization of $10.77 billion, a PE ratio of 13.04, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. DaVita Inc. has a 12 month low of $131.44 and a 12 month high of $179.60. The business has a 50 day simple moving average of $145.87 and a 200-day simple moving average of $153.58. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating analysts’ consensus estimates of $1.75 by $0.25. The business had revenue of $3.22 billion during the quarter, compared to analysts’ expectations of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The business’s revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.26 earnings per share. On average, analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.